See the DrugPatentWatch profile for Fosphenytoin
Fosphenytoin and phenytoin are both medications used to treat or prevent seizures, but they differ in their chemical formulation and how they are administered. Fosphenytoin is a prodrug of phenytoin, meaning it is converted into phenytoin in the body after administration [1].
How quickly does fosphenytoin work compared to phenytoin?
Fosphenytoin is designed for intravenous (IV) or intramuscular (IM) administration and offers a faster onset of action for treating status epilepticus, a prolonged seizure, compared to oral phenytoin. This rapid delivery is crucial in emergency situations [1].
What are the advantages of using fosphenytoin?
A primary advantage of fosphenytoin is its improved safety profile regarding local tissue damage upon injection. Unlike phenytoin, which can cause severe tissue necrosis if it leaks into surrounding areas (extravasation), fosphenytoin is generally better tolerated locally [1]. It also allows for higher doses to be administered more rapidly and in a smaller volume of diluent, which can be beneficial for patients requiring urgent seizure control [1].
Can fosphenytoin be given as a shot?
Yes, fosphenytoin can be administered both intravenously and intramuscularly. Intramuscular administration can be an option when intravenous access is difficult to obtain or maintain [1].
What is the difference in how they are formulated?
Phenytoin is a poorly soluble compound, which can lead to challenges with IV administration, requiring careful dilution and slow infusion to prevent precipitation and local irritation. Fosphenytoin, conversely, is a water-soluble ester of phenytoin. This solubility allows for easier preparation and administration, and its conversion to phenytoin in the body occurs through phosphatases in the liver and blood [1].
When would a doctor choose fosphenytoin over phenytoin?
Doctors typically opt for fosphenytoin in acute settings where rapid seizure control is necessary, such as in the treatment of status epilepticus, or when IV phenytoin administration is problematic due to potential for extravasation or difficulties with infusion rates. Fosphenytoin is also preferred when IM administration is required [1].
Are there any patent considerations for these drugs?
While specific patent expiration dates can be complex and vary, the patents for original formulations of phenytoin have long since expired. Fosphenytoin, being a later development, would have had its own patent protection period. Information on current patent status for specific formulations or brands can be found on DrugPatentWatch.com [2].